mRNA COVID-19 Vaccine Favorable Among Patients With Myasthenia Gravis
Researchers sought to assess whether the mRNA-1273 vaccine is safe and induces humoral and cellular responses in patients with MG.
Myasthenia Gravis
What’s the Cause Behind Symptom Dissatisfaction in Myasthenia Gravis?
In a cross-sectional study, researchers investigated MG-related and generic factors associated with PASS status among patients with gMG to assess their satisfaction with symptoms.
No New Safety Signals With Long-Term 3,4-DAPP for Lambert–Eaton Myasthenic Syndrome
Researchers sought to present results from the European LEMS registry on safety data and long-term outcomes for patients with LEMS being treated with 3,4-DAP and 3,4-DAPP.
Ultomiris Approved for Generalized Myasthenia Gravis
The approval was based on data from a phase 3 study that included 175 adults with generalized myasthenia gravis who were not previously treated with a complement inhibitor.
Ravulizumab Sustains Improvement in Patients With Generalized Myasthenia Gravis
Researchers reported results from an interim analysis of an ongoing open-label extension to study the safety and efficacy of adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis.
Characteristics of Patients in the Refractory Stage of Myasthenia Gravis
In a retrospective study, researchers investigated the autoantibody profile and clinical characteristics of patients with refractory myasthenia gravis, compared to patients nonrefractory status, based on predefined criteria.
COVID-19 Infection Among Patients With Myasthenia Gravis Impacts Hospital Stay
In a retrospective, observational study, researchers determined the impact of COVID-19 infection in patients with myasthenia gravis.
Clinical Features Identified in Subgroup of Drug-Resistant Myasthenia Gravis
Researchers sought to determine the clinical, immunologic, and therapeutic characteristics in patients with drug-refractory myasthenia gravis and to determine the effectiveness and side effects of drugs used for treatment.
COVID-19 Infection and Myasthenia Gravis Outcomes: How Do Patients Fare?
Researchers sought to assess the outcomes of invasive ventilation, mortality, and hospital length of stay among patients presenting with myasthenia gravis and COVID-19.
Myasthenia Gravis Remission Tied to Anti-Acetylcholine Receptor Antibody Changes
In a retrospective study, researchers analyzed the potential association between anti-acetylcholine receptor antibody serum levels and the clinical improvement of myasthenia gravis.
- Loading...
Loading...
Next post in Neuromuscular Disorders
Loading... 
Loading...